1. Home
  2. CYTK vs TKC Comparison

CYTK vs TKC Comparison

Compare CYTK & TKC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • TKC
  • Stock Information
  • Founded
  • CYTK 1997
  • TKC 1993
  • Country
  • CYTK United States
  • TKC Turkey
  • Employees
  • CYTK N/A
  • TKC N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • TKC Telecommunications Equipment
  • Sector
  • CYTK Health Care
  • TKC Telecommunications
  • Exchange
  • CYTK Nasdaq
  • TKC Nasdaq
  • Market Cap
  • CYTK 4.6B
  • TKC 5.2B
  • IPO Year
  • CYTK 2004
  • TKC 2000
  • Fundamental
  • Price
  • CYTK $58.45
  • TKC $5.73
  • Analyst Decision
  • CYTK Buy
  • TKC
  • Analyst Count
  • CYTK 16
  • TKC 0
  • Target Price
  • CYTK $76.73
  • TKC N/A
  • AVG Volume (30 Days)
  • CYTK 2.0M
  • TKC 3.2M
  • Earning Date
  • CYTK 11-05-2025
  • TKC 11-06-2025
  • Dividend Yield
  • CYTK N/A
  • TKC 4.13%
  • EPS Growth
  • CYTK N/A
  • TKC N/A
  • EPS
  • CYTK N/A
  • TKC 0.27
  • Revenue
  • CYTK $85,738,000.00
  • TKC $4,477,789,455.00
  • Revenue This Year
  • CYTK $363.61
  • TKC $41.27
  • Revenue Next Year
  • CYTK $64.08
  • TKC $29.26
  • P/E Ratio
  • CYTK N/A
  • TKC $8.39
  • Revenue Growth
  • CYTK 2635.74
  • TKC 1.16
  • 52 Week Low
  • CYTK $29.31
  • TKC $5.35
  • 52 Week High
  • CYTK $63.86
  • TKC $7.63
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 60.20
  • TKC 43.53
  • Support Level
  • CYTK $58.84
  • TKC $5.42
  • Resistance Level
  • CYTK $63.86
  • TKC $5.81
  • Average True Range (ATR)
  • CYTK 2.52
  • TKC 0.11
  • MACD
  • CYTK -0.26
  • TKC -0.04
  • Stochastic Oscillator
  • CYTK 47.43
  • TKC 39.61

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About TKC Turkcell Iletisim Hizmetleri AS

Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes high-quality mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Turkcell International, and Techfin. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.

Share on Social Networks: